Prediction of ovarian hyperstimulation syndrome in women undergoing in vitro fertilization

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 12, 2009, Pages 1373-1381

  Kahnberg, Annika ^a   Enskog, Anders ^b   Brännström, Mats ^b   Lundin, Kersti ^b   Bergh, Christina ^b  

^a ÅCS   (Finland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

GnRH agonist; In vitro fertilization; OHSS; Prediction; ROC

Indexed keywords

CHORIONIC GONADOTROPIN; INFUSION FLUID; LOW MOLECULAR WEIGHT HEPARIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR ASPIRATION; HOSPITALIZATION; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOEMBOLISM;

ADULT; CHORIONIC GONADOTROPIN; FEMALE; FERTILIZATION IN VITRO; HUMANS; MULTIVARIATE ANALYSIS; OOCYTES; OVARIAN FOLLICLE; OVARIAN HYPERSTIMULATION SYNDROME; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 72049101887     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903287482     Document Type: Article

References (30)

1. Golan A, Ron-EL R, Herman A, Sofer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: An update review. Obstet Gynecol Survey. 1989;44:430-440
2. Schenker JG, Weinstein D. Ovarian hyperstimulation syndrome: a current survey. Fertil Steril. 1978;30:255-268
3. Rizk B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod. 1991;6:1082-1087
4. Enskog A, Henriksson M, Unander M, Nilsson L, Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 1999;71:808-814
5. Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995;27:344-346
6. Beerendonk CC, van Dop PA, Braat DD, Merkus JM. Ovarian hyperstimulation syndrome: facts and fallacies. Obstet Gynecol Surv. 1998;53:439-449
7. Fineschi V, Neri M, Di Donato S, Pomara C, Riezzo I, Turillazzi E. An immunohistochemical study in a fatality due to ovarian hyperstimulation syndrome. Internat J Legal Med. 2006;120:293-299
8. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559-577 (Pubitemid 35452781)
9. Kwee J, Elting ME, Schats R, McDonnell J, Lambalk CB. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol. 2007;5:9.
10. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249-261
11. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85:112-120
12. Macklon NS, Fauser BC. Follicle-stimulating hormone and advanced follicle development in the human. Arch Med Res. 2001;32:595-600.
13. Macklon N, Fauser BC. Regulation of follicle development and novel approaches to ovarian stimulation for IVF. Hum Reprod Update. 2000;6:307-312
14. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol. 1988;159:210-215
15. Delvigne A, Dubois M, Battheu B, Bassil S, Meuleman C, De Sutter P, et al. The ovarian hyperstimulation syndrome in invitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction. Hum Reprod. 1993;8:1361-1366 (Pubitemid 23265962)
16. Meirow D, Schenker JG, Rosler A. Ovarian hyperstimulation syndrome with low oestradiol in non-classical 17 alphahydroxylase, 17,20-lyase deficiency: what is the role of oestrogens? Hum Reprod. 1996;11:2119-2121
17. Papanikolau EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, et al. Early and late ovarian hyperstimulation syndrome:early pregnancy outcome and profile. Hum Reprod. 2005;20:636-641
18. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update. 2003;9:275-289
19. D'Angelo A, Amso N. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane database Syst Rev (Online). 2002:CD002811.
20. D'Angelo A, Amso N. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome. Cochrane database Syst Rev (Online). 2002:CD002806.
21. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin- releasing hormone antagonists for assisted conception. Cochrane database Syst Rev (Online). 2006;3:CD001750.
22. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and a meta-analysis. Hum Reprod Update. 2006;12:651-671
23. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2004;81:1-5.
24. Fauser BC, De Jong D, Oliviennes F, Wramsby H, Tay C, Itskowitz-Eldor J, et al. Endocrine profiles after triggering of final maturation with GnRH agonist after cotreatment with the GnRHantagonistganerelixduringovarianhyperstimulation for in vitro fertilization. J Clin Endocrinol Matab. 2002;87:709-715
25. Kolibianakis EM, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, et al. A lower ongoing pregnancy rate can be expected when GnrH agonist is used for triggering final oocyte maturation instead of hCG, in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005;20:2887-2892
26. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Gröndahl ML, Westergaard L, et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ ICSI cycles: a prospective randomized study. Hum Reprod. 2005;20:1213-1220 (Pubitemid 40796107)
27. Griesinger G, Diedrich K, Devroey P, Kolibianakis EM. GnRH agonist for triggering final oocyte maturation in the GNRH antagonist ovarian hyperstimulation protocol: a systematic review and a meta-analysis. Hum Reprod Update. 2006;12:159-168.
28. Humaidan P, Bredkjaer HE, Westergaard LG, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2009. (Epub Feb 5, 2009) (in press).
29. Heijnen EM, Eijkemans MJ, De Klerk C, Polinder S, Beckers NG, Klinkert ER, et al. A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet. 2007;369:743-749
30. Karlstrom PO, Bergh C. Reducing the number of embryos transferred in Sweden-impact on delivery and multiple birth rates. Hum Reprod. 2007;22:2202-2207